A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
Kim, Kenneth H., Dmitriev, Igor P., Saddekni, Souheil, Kashentseva, Elena A., Harris, Raymond D., Aurigemma, Rosemarie, Bae, Sejong, Singh, Karan P., Siegal, Gene P., Curiel, David T., Alvarez, RonaldVolume:
130
Langue:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2013.06.003
Date:
September, 2013
Fichier:
PDF, 608 KB
english, 2013
File converter
Plus de résultats de recherche
More benefits 
